Hrt Financial LP Adverum Biotechnologies, Inc. Transaction History

Hrt Financial LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$1.5 - $2.33 $37,647 - $58,478	25,098 New	25,098 $37,000
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $261,276 - $414,219	-212,420 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.74 - $2.4 $1.11 Million - $1.53 Million	-635,547 Reduced 74.95%	212,420 $373,000
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $1.76 Million - $3.05 Million	847,967 New	847,967 $1.84 Million
Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $675,044 - $1.05 Million	-72,899 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$9.84 - $14.26 $717,326 - $1.04 Million	72,899 New	72,899 $790,000
Q1 2020 May 15, 2020	SELL	$7.98 - $16.32 $205,772 - $420,827	-25,786 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$5.12 - $12.22 $25,835 - $61,662	-5,046 Reduced 16.37%	25,786 $297,000
Q3 2019 Nov 14, 2019	BUY	$5.24 - $15.89 $161,559 - $489,920	30,832 New	30,832 $168,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.